Physician profile
Tammy E Schuler
NPI 1487748497
$3,662.61
in general payments reported to CMS, 2019-2025
12 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $37.06 · 2021: $236 · 2022: $641 · 2023: $707 · 2024: $654 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,053.08 | 2021-2025 | Total30, Precision7, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $525.50 | 2022-2025 | Cequa |
| Bausch & Lomb Americas INC. | $520.82 | 2023-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $416.78 | 2020-2025 | Acuvue |
| Coopervision INC. | $290.99 | 2023-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.53 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $237.64 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $123.33 | 2022-2025 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $82.82 | 2022-2024 | Spectacle Lenses, Contact Lens |
| Allergan, INC. | $78.15 | 2022 | |
| Abbvie INC. | $53.26 | 2022-2023 | Lumigan, Alphagan P |
| Amgen INC. | $14.71 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Schuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.